All right. Well, thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS. Very excited to have members of the team from Denali Therapeutics up here with us. Ryan Watts, Chief Executive Officer, Katie Peng, Chief Commercial Officer. We get to talk about commercial sales, revenues, raising guidance recently. Alex Schuth, Chief Financial and Operating Officer. Great to see you guys.
Great to be here. Thanks, Mike.
Great to be here.
Yeah. Look, 2026 has been a transformative year for Denali. You got your first approval, been launching your product and raising guidance, as I said. Obviously, so much pipeline here. I told my colleagues we don't have time to go through all six of these programs, so we'll try to keep it focused. I think obviously most important, it's critical to talk about the approval and the successful launch of AVLAYAH, if I got that right.
That's perfect.
Perfect, AVLAYAH. I would love to talk about that. Ryan, why don't you take a chance to tell us about how the progress of that launch is going? Maybe Katie could talk a little bit about how that's going as well, because you raised guidance. As I was commenting with Alex, all this has happened, but then the stock goes up and it comes back down, so we're a little bit puzzled by that. Maybe you could have the opportunity to tell investors about how the launch is going.
Yeah, absolutely. Great to be here, Mike. Thanks for the invitation. Love being here in London. Just a quick introduction, I will hand it to Katie on the launch. As you pointed out, a transformative year, probably the simplest way to describe Denali now is that we have a product in AVLAYAH that validates our platform, the TransportVehicle platform, which then enables our pipeline.
Yep.
I think my sense is, first of all, from a company perspective, it's been an extraordinary year. It's really exciting to launch a product, especially many of the scientists who invented the TransportVehicle, who have been involved in its development, and now ultimately in this launch, have been with us now for the 11 years of our existence. What we're seeing is this incredible experience in the patient community. I think that's most exciting, to see the impact that AVLAYAH is having. In addition to that, now knowing that we can take our platform and apply it to other products. I think the question is, how big can Hunter be? How big can Hunter and Sanfilippo together be?
This platform is not just about treating enzyme replacement therapies or replacing enzyme replacement therapies with molecules that can cross the blood-brain barrier or improve delivery to brain or muscle, but it's also about using this technology in Alzheimer's disease.
We'll get to those, because those are multi-multi-billion.
Exactly.
More and more data is coming out proving it works.
In terms of the launch, I'm going to hand it to Katie to give us an update.
Great. I mean, specifically on the launch, we're super pleased with the trajectory. We reported close to $18 million last quarter, which was significantly higher than our $10 million-$12 million in guidance. Largely, that is driven by the acceleration of payer access. We were able to unlock commercial and Medicaid payment very quickly. In addition, we had a great bolus of our EAP patients, our clinical trial patients, come onto treatment in Q3, which was much sooner than we expected. Those patients were all at the highest dose. In addition, we've heard tremendous feedback from physicians and especially from the families on how well the patients are doing on AVLAYAH. We also discussed bringing in the S-shaped curve.
We talked about rare disease launches having this S-shaped curve, but that we are bringing that inflection in sooner because of the momentum we're seeing behind the launch. We said, between Q2 and Q3, that's probably not the run rate you would expect to see, but we expect strong growth, especially between 2026 and 2027. That inflection is coming, and we're building on a very strong patient base. Generally, in rare disease, persistence is high, so we expect really good, strong growth.
You did $18 million. That was higher than consensus.
Yes
Guidance. You guided for Q4.
Yes.
Tell us about that guidance, because what you said is a lot of this early growth, although I am not sure you have quantified it, has been patients who have also been able to swap from existing.
Yes.
Of those patients you have, and I guess you could divide the revenues by the price and kind of come up with some patients, we have that estimate. But how much of that is new patients that are swapping from obviously Elaprase versus people who are on your drug already? That is an easy swap.
Yeah. It is a great question. We guided to $30 million-$32 million in this coming quarter, and majority actually of patients are a switch from Elaprase.
From Elaprase.
Yes. Because about 95% of patients in MPS II was treated already with enzyme replacement therapy. We talked about wanting to be the market leader in our eligible patient population, right? That would be dominant market share in our pediatric population, but also being able to treat all of the new patients, and the physicians would select AVLAYAH to start new patients as well. But the dominant prevalent patient is on Elaprase, so they're switches. All of our patients are switches.
Okay. We've done some estimates, but remind me how many people you think are in the prevalent swap pool that you think you could go after for Hunter in your label?
Yeah. The total U.S. population with Hunter syndrome is 500 patients, and of that, our FDA label makes eligible patients to be 375.
Okay.
We believe the entire pediatric population is eligible for AVLAYAH. In thinking about neurologic manifestations, you talk to physicians today, and almost all patients at some point in time will develop neurologic manifestations.
Okay.
Preventing it or treating it are really critical to HCPs.
I won't get too far ahead of guidance. I'm not sure you're going to guide early 2027. You can tell me if that's a reasonable or not reasonable expectation, guidance for 2027. But would you expect to get a majority of those patients, 350 + in 2027? You think that's reasonable?
Maybe I'll let you address the guidance piece, Alex. But in terms of our goal, it is absolutely to become the market leader as soon as possible.
Okay. Which is majority.
Which is majority.
Okay.
Exactly.
Is that something that's doable in a pretty quick timeframe?
Yeah.
Absolutely. We believe the way the trajectory is going, we believe that next year, we can become the market leader in Hunter syndrome. To the point on the guidance, we wanted to provide the market the best picture of how we see the launch going, which is why we decided to provide revenue guidance for the first quarters in 2026. We have not made a decision yet if we continue that guidance going forward, because I think it will become less relevant once we're actually on the trajectory.
All right. Quarterly guidance is good, annual guidance is good. We have our own analyst estimates for that. I think you should be at 50% of those patients. Appreciate that. Then just lastly on this before we get to the meat of some of this pipeline is, tell us about the confirmatory study. My understanding is that the data would be coming, I say next year, but we're already in 2027, but in 2028. To what extent do you feel confident or greater than 50% or 60% or 70% confident that that's going to hit the primary endpoint? As an analyst, I would say if it's close but doesn't hit statistical significance, I don't think the FDA is going to get too bent out of shape about it. But we do want to have statistical significance on a confirmatory study.
Yeah, just a reminder of the COMPASS study design, just briefly. There are 56 patients split between two cohorts. Cohort A, which is focused on really the neurologic manifestations of disease, and cohort B, which is the more systemic manifestation of disease. We designed this study focused on two co-primary endpoints. The first is CSF heparan sulfate, which of course we have shown the ability to reduce CSF heparan sulfate by 90% +. That is the approvable endpoint for the accelerated approval. The second co-primary endpoint is actually Vineland. It is actually a composite of the Vineland. There we have also shown and published in the New England Journal improvement in behavior. Also, the secondary endpoints will be like Bayley, which is a measure of cognition in younger patients.
In the cohort B, we are looking at not just six-minute walk, but also important peripheral biomarkers like urine heparan sulfate, liver and spleen volume. Basically, all of these endpoints we have shown data before, and we have presented the data in the New England Journal article that was published earlier this year. So we are confident in the design of the trial. The reality is that it is an ultra-rare disease, and therefore, you can always power these things. You wish you could power them greater, but we are in a, I think, a very strong position. In addition to that, incredible real-world data from the launch of AVLAYAH. So in terms of timing, the cohort A is the sort of rate-limiting step. All patients will reach a two-year endpoint by the end of next year, as you point out, and therefore it will be 2028.
Why is this study important?
It is important for two reasons. One is expansion of the label.
Yep.
Okay? The second is to be able to file outside the U.S. in key, I will call it, the last 1/3 of the market. So when we think about the market, we are accessing the U.S., and then there is 1/3 of the market that we can access right now that we are actively pursuing, and then the last third will be enabled by the COMPASS data.
Okay. Yeah, it is important because not only does it serve as a confirmatory study, but it also is required because outside the U.S., they do want a randomized controlled study.
That is right.
For that. We have done work around that. I would say I am not 90% confident. Maybe you can get me 90% confident. But there is a view that the placebo will continue to decline, excuse me, the Elaprase will continue to decline, and obviously your drug should offer protection. Therefore, they should have modest or much no decline. In fact, improvements.
Yeah. That is actually key. We have seen significant improvement. I think for us, the data that we use, there are some natural history data. Actually, there are large studies like the intrathecal Elaprase study where that data is really helpful to sort of predict, seeing that that particular approach did not reduce neurofilament, which is a key marker of neurodegeneration. You can kind of pull that data. Then, of course, our own phase I/II data that increases our confidence in that study.
Right. Okay. All right. We will look forward to that. That is in first half 2028. Now, I would like to go briefly to the Sanfilippo program because this goes back to your thesis that if it is approved, validates, FDA is all good with the accelerated approval on Hunter, basically Sanfilippo type A should have the same regulatory endpoints and the same heparan sulfate endpoints, and that should be an accelerated filing. I think it is a little bit of a smaller market than Hunter. Combined, these can be $1 billion or more. But maybe talk about where you are with Sanfilippo because it is literally the same regulatory filing and the same endpoint.
Right. As you point out, the Hunter filing and AVLAYAH leading the way.
Yeah.
Sanfilippo, there are key similarities and some key differences. Sanfilippo is actually primarily a neurological disease, where Hunter is much more whole body, including the brain. That being said, there are peripheral manifestations of disease in Sanfilippo, for example, enlarged liver and spleen. The data that we have presented show normalization of liver and spleen, a robust reduction in heparan sulfate with the ability to normalize as well. Those patients that do not normalize, like most enzyme replacement therapies have usually anti-drug antibodies, so continued dosing or changing the dose regimen. That is what we learned from the first eight patients. That data was presented at WORLDSymposium. Today, that is the most robust data set and biomarkers in all.
By the way, no approved drugs here.
That's right. Well, that's not correct. There was just a gene therapy approved by Ultragenyx, which was originally developed by Abeona.
Okay.
That one shows about 50%, 60% reduction in CSF heparan sulfate. I won't go into more detail, but beyond maybe saying that there may be an impact, for example, in liver. There's room for improvement, no doubt. This particular medicine, ZAFY, as we call it, has that ability to robustly reduce heparan sulfate and treat brain, but also body.
Right. They had some data, it wasn't approved. Is this a direct injection?
It's actually not. That's an interesting point about it.
Yeah.
There are two ways to approach gene therapy in the lysosomal storage diseases. In Hunter, there was a direct injection in the brain, but for Sanfilippo, this is an AAV9 delivered system.
Okay. This would be like, okay, well, they have some data, but that's a one-time therapy. Yours is an enzyme replacement therapy, much more traditional approach, has stronger data.
Yeah.
Both peripheral and CNS effect.
That's right. I think the key here is, the way to look at it is, when you think of gene therapy, you think about durability and effect size. The way we view it is, it's probably going to be either you go just on ZAFY or you add it on top of gene therapy over time. That's actually how we viewed it as well in Hunter syndrome, where in that case, it was injected directly in brain. That program is currently not advanced.
Where are you with the status of this program and the potential filing?
Yes. We've just completed the 49-week portion of the study in September. Database lock is now preparing data. We're going to share data at WORLDSymposium, which is essentially the pivotal data for the BLA filing, which is really important. We're excited about that data in February. Basically, the timing of filing is being driven mainly by what we call Module 3, or what everyone calls Module 3, which is the manufacturing.
Okay.
Unlike AVLAYAH, which we manufactured actually outside the U.S., with Lonza, we're manufacturing ZAFY ourselves in our own facilityâ
Okay
âin the U.S. Basically, that's going to be our first launch, obviously, from our own facility. That's what we're really focused on, is being ready for inspection and ready to launch our own commercial product. Part of that is just driving the maximizing COGS and really bringing our manufacturing to the highest level, which when you manufacture a commercial product, that is the highest level.
Yeah. Look, it's great to have your own in-house manufacturing. That's important. By the way, could you move Hunter to that as well?
We've thought about that. The issue with moving Hunter is that we're actually, thanks to Katie and a successful launch, we need to scale it up from 2,000 L to 6,000 L. Our facility is two 2,000 L.
Okay.
Too much detail, but it makes sense for us to stay with Lonza. They've been a great partner, and we're going to scale that up also in the U.S.
Well, for Sanfilippo, your ability to do that obviously includes COGS.
Yep.
There's not a third-party markupâ
Right
âor taking off of that. Okay.
It does that. I'll just also point out, because we're going to go to the rest of the pipeline. All of our other products, including our Pompe medicine, obviously FTD-GRN, but our Alzheimer's medicines, we manufacture ourselves now. Across the board, elevating our own manufacturing. I think the way that Alex likes to describe it, and Alex, if you want to give more detail, is that we've spent enough on manufacturing for AVLAYAH that we can build our own facility and within one or two products
Okay. Now, let's talk about the blood-brain shuttle for neurological diseases like Alzheimer's and others. Look, Ryan, we have talked about this for years, right? I've been excited about this because we're talking about multi-billion dollar indications, and particularly where taking an antibody and dragging it through the blood-brain shuttle to target things like A-beta or obviously MAPT, it makes every sense in the world, because it's very difficult with an antibody or an ASO. This is exactly where your technology platform can shine. Now, with tau, in a positive, we had positive phase II data from Biogen, and they have since pushed that to a planned phase III. I would argue that tau does have cognitive benefits. We can debate the statistical significance and all of these different things, but there's pretty good proof of concept.
Tell us about your MAPT program, and tell us why you think it would be much better than Biogen's naked ASO, and what have we learned from Biogen? Because by the way, I think there's data this week.
Today.
Today.
Yeah.
Did we get the data already yet? But, oh, what would you learn from that?
If this happens live, just let us know.
Okay, just let us know. We'll webcast it in here.
Yeah.
What would we learn from it? The audience knows that the Biogen data is positive trends and overall looks good. Again, I don't want to debate statistical significance, but what would you want to learn, and then why is your product going to be better?
Yeah. I'll start with a general comment and then go specifically down to MAPT. As you point out, Mike, we've been discussing this for the 11 years ofâ
Yes
âour existence. With the first FDA-approved platform in the TransportVehicle, it's perfect for us to use this TransportVehicle now to go after different modalities and different therapeutic areas. I will say, 11 years ago, I didn't imagine how rewarding it would be to focus on the rare diseases like Hunter and Sanfilippo, and it's become a real area of focus. We can build a real and frankly robust business, which will then fuel our opportunity to go after some of these other areas.
The enzyme replacement business can be a billion-dollar business generatingâ
Yeah
âcash flow to support long-term.
Yeah, and I think actually if you look at the four enzymes that we have in addition to Pompe and then obviously GCase and Gaucher, and we put FTD-GRN in there as well, this is $3 billion-$4 billion in peak revenue just in those programs alone, which have very high probability. Now, go back 10 years and then come today, and you realize you now have A-beta as a validated target in Alzheimer's.
Approved drugs, yeah.
You have with approved drugs. The interesting thing about enzymes, it is unlocking. For Alzheimer's, it is enhancing. What I mean by that is you have approved drugs, they are standard antibodies, only a fraction of that antibody gets across the blood-brain barrier, but they are slowing neurodegeneration. Now we can dramatically enhance that. That has been shown by others, and we obviously have our own product where we are in phase I right now. With MAPT, now going very specifically to MAPT, this could be, and I would argue, having worked in the Alzheimer's space also for two decades, both blood-brain barrier and Alzheimer's, that this is the second clinically validated target. The reason why the data presented in July were confusing was this inverse dose relationship looking at the CDR-Sum of Boxes. If you look at MMSE and ADAS-Cog, those were statistically significant at all doses.
CDR-Sum of Boxes was significant at the low dose and less so, not significant at the mid and high dose, but some complications with intrathecal delivery. You can either interpret it as you need to get a certain amount of tau reduction to optimize the benefit, or there is some limitation to intrathecal delivery. You can interpret it either way.
Well, what do you mean by that point? Just to be Overall, I just want to say that Wall Street looked at the data. We think there is some positive trends.
Yeah.
I got to be honest, they do not have a lot of patience for looking at Alzheimer's data these days, focused on a million other things. It worked at the low dose, did not work at the higher doses, but every other endpoint besides CDR-Sum of Boxes has some pretty strong trends.
Yeah.
What you're saying aboutâ
Yeah, I'll just add one sort of corrective note to that. It worked statistically significant at the low, medium, and high dose for ADAS-Cog and forâ
Sure
âMMSE.
Yeah.
In the CDR-Sum of Boxes, which was the primary endpoint, it was the low dose that showed the greatest benefit, right?
Yeah.
Now, I think what you need to I don't want to go into too much detail because I'm not developing an intrathecal medicine. I should talk about the OTVâ
Yeah
âwhich is the Oligonucleotide TransportVehicle .
But the idea of why does tau work?
Yeah.
Tau, yeah.
Yeah, and I think that. So why does tau work? If you look at all the data, basically tau is downstream of A-beta, neurofibrillary tangles, and the pathology associated with neurofibrillary tangles correlates with cognitive decline. In other words, plaque happens 20 years before disease, then you start to develop tangles progress as disease progresses. This is a likely downstream second target. I think very exciting on its own, also very exciting in combination with A-beta.
Your program is going to take an ASO, I assume it is pretty similar to the Biogen one, but we are tagging the TfR shuttle to it and dragging the ASOâ
That is right.
âway more efficiently and way more powerfullyâ
Yeah
âthan a naked antibody.
That is right.
Through intrathecal.
Yeah, I think that the biggest issue is with intrathecal, you have very high concentrations in the spineâ
Okay
âand you have uneven concentrations in the brain.
Okay.
When you use the TransportVehicle, you get even distribution throughout the entire central nervous system, and that's because you're crossing the capillaries. That's been well-documented across species. I think that's also translating into human. The best example we have is that Elaprase was given intrathecally and did not work, but AVLAYAH robustly works. Not only the biomarkers translate to clinical benefit, but you're seeing really good clinical outcomes with that approach.
Yeah
It's similar with an intrathecal delivery of an ASO, you're going to have this uneven distribution, and that's what the TransportVehicle enables, is that even knockdown.
If we believe that it's going to be better and more efficiently drives a lot more even distribution and a lot more uptake of the ASO through an IV than through the blood-brain barrierâ
Yeah
ârather than intrathecal injection.
Yeah
What do you want to see in your phase I? What is theâ
Yeah.
âtimeline? What are we going to see?
For us, I think it's really important to look at the initial biomarker, so tau reduction. But when you're looking at tau reduction, just like we look at CSF heparan sulfate in Hunter, our conclusion is that reduction is even throughout the brain.
Okay
Unlike the intrathecal approach, right? So that's definitely one.
Not just a reduction, it's a reduction evenly across.
That's right. You're looking at CSF tau.
Yeah.
That would be the first what we look at. The second, we will be looking at tau PET. That will take longer. The data that has been presented so far, which is actually pretty interesting, that even with the intrathecal, you get a reduction in tau PET. There may be some unevenness to that, obviously, as we have discussed, but that is going to be interesting. That will take a bit longer to look at that data. And then ultimately, it is clinical benefit. You have to run the trial. Our goal in the phase I-B is identify the dose that we hit our target knockdown, and let us say, somewhere between 30% and 60%. We do not really know what that range is. All the preclinical data says anywhere between 25% and 50% even is really robust in terms of providing a clinical benefit.
You basically need to see believable knockdown, and then you need to run the clinical trial where you are looking at cognitiveâ
Remind me the numbers. Biogen has shown how much CSF knockdown?
Yeah, so the low dose is about 40%, 45%.
Okay.
The high dose was about 60%. There's not a Surprisingly, even though the dose was two and four-fold higher, there wasn't a big, big differenceâ
Okay
âin the tau knockdown.
But there were 45%-60% knockdown in the CSF.
That's right.
If you hit that kind of general range, your point is that we're also not only having that, but it's more evenlyâ
That's right.
âdistributed.
That's exactly right.
Okay. That's an important biological benefit. tau PET, that is different. tau PET, you're actually measuring it on an image.
Right.
We love to see that because PETâ
Right
âA-beta, I think we all agree that that is very validated. In factâ
That is right.
âFDA even counts that as, at one pointâ
Right
âas acceptable. How much tau PET reduction do you want to see?
Yeah, a little bit harder to quantify what you expect. That's about a regional accumulation. Tau is interesting because it spreads across regions. You're looking for essentially halting the spread, but you would also love to see a reduction in maybe the originating region as well. What's interesting is the kinetics of that has been different. There was data showing six months, there was no change essentially with intrathecal delivery, and then they saw a change at two years. The more recent data suggests that you can see some change at one year. Even though you knock down tau, what it's doing is there must be an equilibrium with the neurofibrillary tangles. When you reduce total tau, you essentially start shifting that, and you start to see that neurofibrillary tangles are probably unwinding, if you want to call it that.
Okay.
A little different than amyloid plaque, because amyloid plaque, what you have is microglia that engulf the plaque.
The antibody coats the plaque, and then actually microglia come in and engulf it. It's very different than the intracellular pathology of neurofibrillary tangles.
The first readout on CSF tau reduction would be when?
That is next year, and that drives dose. Basically, we know what we want to hit. We want to drive dose. Once you pick that dose, then you are ready to go do the broader clinical studies. We will also look at tau PET, but I am providing the bookends, which is, could take as long as two years, as short as one year. No one has shown more rapid tau reduction than a year. But we will see what the BBB technology [crosstalk]
Look, I would argue that having a significant CSF tau reduction and knowing that the drug is getting to where it is going to and it is safe and getting the same type of reductions as Biogenâ
Yeah
âwould be that you are at least getting the same biological tau reduction in a much better, more efficient dose because it is IV and not intrathecal.
Right.
That you can probably push up as much as you can without having any safety issues. You should go right to a phase II-B.
Yeah
Why would I want to wait a year ago to watch that tau go [crosstalk]
Or even a phase II/III, one that's powered enough to look at clinical endpoints.
Okay.
I think that's a likely approach.
Okay.
We obviously are spending a lot of time thinking about how we develop our A-beta molecule and our tau molecule.
Okay.
We are very invested in Alzheimer's disease because we see these platforms.
Yeah.
Specifically, the TransportVehicle as being transformative to enable subQ, to enable robust reduction versus intrathecal.
I will look forward to the CSF tau reduction. I would appreciate and acknowledge that I do think that the timelines are long because we need to go run the clinical studies. Even for Biogen, we got to see if the Biogen result is going to be positive.
That's right.
However, in the last couple minutes, in ATV:Abetaâ
Right
âto pull an A-beta antibody and use that to get rid of plaque to improve Alzheimer's disease is about as validated as ever because now we have two approved naked antibodies. No doubt that the Roche trontinemab data, everybody agrees is pretty good. I got to say, Wall Street's not paying too much attention because there's a lot of other things going on in the world. It's Roche, so no one's trading Roche on this data. But the result should be positive for the trontinemab A-beta shuttle and show pretty strong efficacy and much less ARIA. That's great. So your drug is a higher probability of successâ
Right
âthan the tau.
Yeah.
What are the timelines for this? Not only is Roche trontinemab in a phase III, and I think the data is coming first half 2028, but others are following you, like Korsana and some of these others.
Yes, of course. I mean, for us, 2027 is also a key year for the A-beta program. Let's identify a dose that is safe, well-tolerated, and reduces plaque. That is going to be the key. There is room for improvement on trontinemab around both hematology and specifically around infusion-related reactions.
Okay.
That is really important. We will start with healthy volunteer, very quickly go to patients and look at plaque reduction. There, it is identify dose and go. I think the other thing is subQ, enabling a subQ is going to be key, which at this point, trontinemab is IV.
Okay, you can use subQ?
That is the goal for our Alzheimer's.
What exactly is the timing on MAPT? You are in phase I.
Yeah, so both MAPT and A-beta data 2027.
And will you just Because I am not sure I care about healthy volunteer data. You will have Alzheimer's data.
That is the goal as well.
in 2027? That would include PET reduction at three months, six months?
Yeah, we haven't gone into detail on the study design, but PET reduction is the goal there because that's how we're going to.
In 2027?
Yeah, exactly.
Okay. Like Korsana Biosciences, another company, they're dosing, they're just going to show you the trajectory of it. And they say, "See, we're on the trajectory of trontinemab. We have trontinemab.
Got it.
Okay. Thank you very much, guys. A whole lot going on. Thank you for all these updates, continued commercial execution and pipeline. Very excited about all this in 2027.
We only got halfway through it.
I know. Got another R&D Day coming up.
That's right.
Thank you guys very much.
Thank you.
Thank you.